OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.

OvaRex (oregovomab) - CanariaBio

http://www.ncbi.nlm.nih.gov/pubmed/38940373

Chel Hun Choi; Hyun Woong Cho; Jung-Yun Lee; Junsik Park; Myong Cheol Lim

Jun 28, 2024